Tag: Inflectra

Pfizer, Celltrion say data backs switch to Remicade biosimilar

by Selina McKee | Oct 31, 2017 | News | 0

Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.

Biosimilar Inflectra matches Remicade efficacy in trial

by Selina McKee | Feb 20, 2017 | News | 0

Pfizer and Celltrion have unveiled Phase III study data comparable safety and efficacy between biosmilar Inflectra and reference drug Remicade in patients with moderate-to-severe Crohn’s disease (CD).